Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical Mutations: A Phase Ib Study.
[PURPOSE] To evaluate the safety and efficacy of izalontamab brengitecan (iza-bren) in patients with non-small cell lung cancer (NSCLC) harboring actionable genomic alterations (GAs) outside of classi
- 표본수 (n) 14
APA
Zhou H, Zhao H, et al. (2026). Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical Mutations: A Phase Ib Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(10), 893-902. https://doi.org/10.1200/JCO-25-01929
MLA
Zhou H, et al.. "Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical Mutations: A Phase Ib Study.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 44, no. 10, 2026, pp. 893-902.
PMID
41779981
Abstract
[PURPOSE] To evaluate the safety and efficacy of izalontamab brengitecan (iza-bren) in patients with non-small cell lung cancer (NSCLC) harboring actionable genomic alterations (GAs) outside of classical epidermal growth factor receptor () mutations.
[METHODS] Eligible patients had locally advanced or metastatic NSCLC with prespecific actionable GAs, had progressed after standard treatment and received no more than one previous line of chemotherapy. iza-bren was administered at the dose of 2.5 mg/kg once per day on days 1 and 8 of each 3-week cycle. The primary end point was safety. The secondary end points included objective response rate (ORR), disease control rate (DCR), and duration of response. The exploratory end points included progression-free survival (PFS) and overall survival (OS).
[RESULTS] A total of 83 patients with NSCLC were enrolled in four cohorts: exon20ins/nonclassical mutations (n = 14), human epidermal growth factor receptor 2 () mutation (n = 19), // mutation (n = 26), and /// fusion (n = 24). The most common grade ≥3 treatment-related adverse events (TRAEs) were thrombocytopenia (51.8%), anemia (44.6%), and neutropenia (43.4%). The most frequent nonhematologic TRAEs of all grades were nausea (49.4%), asthenia (45.8%), stomatitis (44.6%), and diarrhea (38.6%). One case of grade 2 interstitial lung disease was observed. The confirmed ORR was 39.7%, and the DCR was 85.9%. The median PFS was 7.0 months (95% CIs, 5.4 to 10.5), while OS data were immature. Patients with exon20ins or other nonclassical mutations achieved an ORR of 69.2% with a median PFS of 10.5 months (95% CI, 6.9 to not reached); the -mutant cohort had an ORR of 52.9% and a median PFS of 7.5 months (95% CI, 5.4 to not reached).
[CONCLUSION] iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical mutations, especially in exon20ins/nonclassical and mutations.
[METHODS] Eligible patients had locally advanced or metastatic NSCLC with prespecific actionable GAs, had progressed after standard treatment and received no more than one previous line of chemotherapy. iza-bren was administered at the dose of 2.5 mg/kg once per day on days 1 and 8 of each 3-week cycle. The primary end point was safety. The secondary end points included objective response rate (ORR), disease control rate (DCR), and duration of response. The exploratory end points included progression-free survival (PFS) and overall survival (OS).
[RESULTS] A total of 83 patients with NSCLC were enrolled in four cohorts: exon20ins/nonclassical mutations (n = 14), human epidermal growth factor receptor 2 () mutation (n = 19), // mutation (n = 26), and /// fusion (n = 24). The most common grade ≥3 treatment-related adverse events (TRAEs) were thrombocytopenia (51.8%), anemia (44.6%), and neutropenia (43.4%). The most frequent nonhematologic TRAEs of all grades were nausea (49.4%), asthenia (45.8%), stomatitis (44.6%), and diarrhea (38.6%). One case of grade 2 interstitial lung disease was observed. The confirmed ORR was 39.7%, and the DCR was 85.9%. The median PFS was 7.0 months (95% CIs, 5.4 to 10.5), while OS data were immature. Patients with exon20ins or other nonclassical mutations achieved an ORR of 69.2% with a median PFS of 10.5 months (95% CI, 6.9 to not reached); the -mutant cohort had an ORR of 52.9% and a median PFS of 7.5 months (95% CI, 5.4 to not reached).
[CONCLUSION] iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical mutations, especially in exon20ins/nonclassical and mutations.
MeSH Terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Female; Male; Middle Aged; Aged; Mutation; ErbB Receptors; Adult; Aged, 80 and over; Crown Ethers; Progression-Free Survival
같은 제1저자의 인용 많은 논문 (5)
- A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice.
- Global and National Burden of Chronic Obstructive Pulmonary Disease and Tracheal, Bronchus, and Lung Cancer From 1990 to 2021: Comorbidity Burden Analysis Based on the Global Burden of Disease Study 2021.
- MTA1 upregulation enhances stemness and chemoresistance of gastric cancer cells.
- Symptom Cluster Trajectories of Cough, Shortness of Breath, and Disturbed Sleep in Patients Undergoing Lung Cancer Surgery: A Longitudinal Study.
- Combination of Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer.